The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus

Erdem G., Dogru T., Tasci I., Bozoglu E., Muhsiroglu O., Tapan S., ...Daha Fazla

Diabetes Research and Clinical Practice, cilt.82, sa.2, ss.214-218, 2008 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 82 Sayı: 2
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1016/j.diabres.2008.07.021
  • Dergi Adı: Diabetes Research and Clinical Practice
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.214-218
  • Anahtar Kelimeler: Visfatin, Pioglitazone, Metformin, Type 2 diabetes
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Aims: Circulating visfatin levels are altered in insulin resistant states. We evaluated the effects of two insulin-sensitizing hypoglycemic agents on plasma visfatin and adiponectin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus (T2DM). Methods: Forty-four patients with T2DM were randomized to treatment either with pioglitazone (15-45 mg/day) or metformin (1000-2000 mg/day). Plasma visfatin and adiponectin levels and homeostasis model assessment of insulin resistance (HOMA-IR) scores were determined at baseline and at 12th week of treatment. Results: By the end of the 12th week, fasting plasma glucose, HbA1c, HOMA-IR scores and waist circumferences improved equally in both treatment arms. HDL cholesterol and adiponectin levels increased only in the pioglitazone group (p = 0.01 and p = 0.003, respectively). On the other hand, metformin treatment had additional regulatory effects on BMI, blood pressure and total and LDL-cholesterol levels (p = 0.002, p = 0.01, p = 0.004, p = 0.001 and p < 0.001, respectively). Neither pioglitazone nor metformin displayed a significant effect on circulating visfatin concentration. Conclusions: Despite improvements in insulin sensitivity and glycemic regulation, either pioglitazone or metformin treatment did not result in any effect on blood visfatin levels in patients with treatment naïve T2DM. © 2008 Elsevier Ireland Ltd. All rights reserved.